We found that the mutation of AHNAK2 was statistical significantly associated with higher ORR (Figure 2C), suggesting that AHNAK2 mutation might predict an improved clinical outcome for NSCLC patients treated with ICIs. Here, AHNAK2 is linked to non-small cell lung carcinoma.